Point Biopharma Global Inc Quick Ratio (PNT) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Point Biopharma Global Inc   (NASDAQ: PNT)

Point Biopharma Global Inc 's Quick Ratio

PNT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 8.77 below Point Biopharma Global Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 122 other companies have achieved higher Quick Ratio than Point Biopharma Global Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 316 to 393.

Explain Quick Ratio?
How much Cash & cash equivalents PNT´s has?
What are PNT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PNT Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 132.82 % 118.95 % 349.53 % 607.97 % 105.19 %
Y / Y Cash & cash equivalent Change 16.34 % 112.21 % 89.12 % 119.92 % 15.3 %
Quick Ratio MRQ 8.77 10.28 7.01 9.3 17.55
PNT's Total Ranking # 393 # 316 # 530 # 386 # 176
Seq. Current Liabilities Change -6.05 % -32.89 % 8.55 % 240.17 % -11.64 %
Seq. Cash & cash equivalent Change -19.86 % -1.58 % -18.12 % 80.16 % 46.17 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 207
Overall Market # 393


Quick Ratio Statistics
High Average Low
29.93 13.65 0.13
(Dec 31 2021)   (Jun 30 2020)




Financial Statements
Point Biopharma Global Inc 's Current Liabilities $ 39 Millions Visit PNT's Balance sheet
Point Biopharma Global Inc 's Cash & cash equivalent $ 339 Millions Visit PNT's Balance sheet
Source of PNT's Sales Visit PNT's Sales by Geography


Cumulative Point Biopharma Global Inc 's Quick Ratio

PNT's Quick Ratio for the trailling 12 Months

PNT Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 246.58 % 261.94 % 268.11 % 262.8 % 117.77 %
Y / Y Cash & cash equivalent TTM Growth 79.45 % 81.83 % 45.67 % 62.33 % 77.97 %
Quick Ratio TTM 8.69 9.51 9.44 11.78 16.78
Total Ranking TTM # 3423 # 2740 # 400 # 3274 # 2749
Seq. Current Liabilities TTM Growth 12.56 % 14.59 % 45.18 % 85.07 % 17.55 %
Seq. Cash & cash equivalent TTM Growth 2.85 % 15.47 % 16.3 % 29.92 % 4.21 %

Quick ratio ranking by company, industry and sector >> Back to PNT Financial Strength Comparisons >> Go to Compare PNT Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2023 to $38.67 millions, cumulative Quick Ratio decreased to 8.69 below the Point Biopharma Global Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 511 other companies have achieved higher Quick Ratio than Point Biopharma Global Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2740 to 3423.

Explain Quick Ratio?
How much Cash & cash equivalents PNT´s has?
What are PNT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 512
Healthcare Sector # 1016
Within the Market # 3423


trailing twelve months Quick Ratio Statistics
High Average Low
25.66 11.61 0
(Dec 31 2021)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Lantern Pharma Inc   21.54 $ 44.926  Millions$ 2.085  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics Inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions
Fulcrum Therapeutics Inc   18.27 $ 257.091  Millions$ 14.075  Millions
Stoke Therapeutics Inc   18.18 $ 214.718  Millions$ 11.811  Millions
Edgewise Therapeutics inc   17.73 $ 289.697  Millions$ 16.338  Millions
Kura Oncology Inc   17.51 $ 452.593  Millions$ 25.843  Millions
Olema Pharmaceuticals Inc   17.34 $ 276.901  Millions$ 15.966  Millions
Keros Therapeutics Inc   17.24 $ 287.893  Millions$ 16.701  Millions
Trevi Therapeutics Inc   17.18 $ 88.868  Millions$ 5.173  Millions
Cadrenal Therapeutics Inc  16.91 $ 9.109  Millions$ 0.539  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.